TCIRG1 Antibody

What are the optimal applications for TCIRG1 antibody in experimental research?

TCIRG1 antibody has been validated for multiple experimental applications with specific recommended dilutions for optimal results:

It's important to note that these dilutions should be optimized for your specific experimental system. For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested, although citrate buffer pH 6.0 may be used as an alternative .

What molecular weight should be observed for TCIRG1 in Western blot experiments?

When using TCIRG1 antibody in Western blot applications, researchers should expect to observe bands at approximately 92 kDa, which corresponds to the full-length protein. Additionally, bands may be detected at 65-70 kDa, which likely represent alternative splicing variants or processed forms of the protein .

The calculated molecular weight based on amino acid sequence is 93 kDa (830 amino acids), which closely matches the observed molecular weight in experimental conditions. Discrepancies between observed and predicted molecular weights may occur due to post-translational modifications or tissue-specific processing .

What are the recommended positive controls for TCIRG1 antibody validation?

For proper antibody validation, the following positive controls have been confirmed for TCIRG1 antibody:

• Western Blot: HL-60 cells, U-937 cells, A431 cells, HuH-7 cells, and SKOV-3 cells have all demonstrated reliable TCIRG1 expression

• Immunohistochemistry: Human stomach tissue shows consistent TCIRG1 expression and serves as an appropriate positive control

• Immunofluorescence: HepG2 cells have been validated for TCIRG1 detection in IF applications

When establishing new experimental systems, including these positive controls alongside experimental samples provides crucial validation of antibody performance.

How can TCIRG1 knockdown experiments be designed to study its functional role in cancer cells?

Based on published research, siRNA-mediated knockdown has been effectively used to study TCIRG1 function. For designing TCIRG1 knockdown experiments, the following validated siRNA sequences have been successfully employed:

siRNA-TCIRG1#1:

• Sense: 5′-GGACCUGAGGGUCAACUUUTT-3′

• Antisense: 5′-AAAGUUGACCCUCAGGUCCTT-3′

siRNA-TCIRG1#2:

• Sense: 5′-CCAUCUACACCGGCUUCAUTT-3′

• Antisense: 5′-AUGAAGCCGGUGUAGAUGGTT-3′

Control siRNA-NC:

• Sense: 5′-GGGUGGAAUUCCAGAACAATT-3′

• Antisense: 5′-UUGUUCUGGAAUUCCACCCTT-3′

Transfection using Lipofectamine RNAiMAX following manufacturer's instructions has shown effective knockdown in 769P and Caki-1 cell lines with 48-hour incubation before subsequent experimental steps. Knockdown efficiency should be verified using qRT-PCR and Western blot before proceeding to functional assays .

What approaches can resolve discrepancies in TCIRG1 expression patterns between different experimental techniques?

Discrepancies in TCIRG1 expression patterns between techniques like IHC, WB, and qPCR may arise due to several factors. To systematically resolve these discrepancies:

• Antibody validation: Ensure the same antibody clone is used across experiments, as different epitopes may yield varied results. The polyclonal antibody targeting TCIRG1 fusion protein Ag3378 has been validated across multiple applications .

• Subcellular localization analysis: TCIRG1 functions within lysosomal membrane structures, so subcellular fractionation prior to Western blot or confocal microscopy with markers for different cellular compartments can clarify if apparent discrepancies reflect localization differences rather than expression levels .

• Tissue/cell heterogeneity: In tumor samples, heterogeneous expression may cause discrepancies between bulk RNA measurements and protein detection methods. Single-cell approaches or laser capture microdissection can address this issue .

• Post-translational modifications: Cross-validation using multiple antibodies targeting different epitopes can reveal whether modifications affect detection in certain applications .

How can TCIRG1 antibody be optimized for multiplex immunofluorescence with other cancer biomarkers?

For multiplex immunofluorescence incorporating TCIRG1 with other cancer biomarkers, consider the following optimization steps:

• Sequential antibody application: Apply TCIRG1 antibody first at 1:10-1:100 dilution, followed by thorough washing before applying other antibodies to prevent cross-reactivity .

• Spectral unmixing: When combining with biomarkers that may share localization patterns, utilize confocal microscopy with spectral unmixing capabilities to distinguish closely related signals.

• Antibody isotype selection: Since TCIRG1 antibody (12649-1-AP) is a rabbit IgG, pair with mouse, goat, or other species-derived antibodies for other biomarkers to enable clean multiplexing .

• Validation controls: Include single-stained controls alongside multiplex samples to confirm signal specificity for each marker, especially important when studying TCIRG1 alongside other lysosomal or immune cell markers .

How does TCIRG1 expression correlate with clinical outcomes in different cancer types?

Research has demonstrated significant correlations between TCIRG1 expression and clinical outcomes across cancer types. In clear cell renal cell carcinoma (ccRCC), high TCIRG1 expression predicts unfavorable clinical outcomes:

These findings suggest that TCIRG1's prognostic significance is cancer-type specific, highlighting the importance of contextual analysis when using TCIRG1 as a biomarker .

What methods can be used to investigate the relationship between TCIRG1 expression and tumor immune microenvironment?

Several validated methodological approaches can be employed to examine the relationship between TCIRG1 and the tumor immune microenvironment:

Research has shown that TCIRG1 is strongly associated with CD8+ T-cell, regulatory T-cell (Treg), and CD4+ T-cell infiltration in ccRCC, suggesting its potential role in modulating anti-tumor immunity .

What are the recommended approaches for studying TCIRG1's role in cancer cell migration and invasion?

To investigate TCIRG1's role in cancer cell migration and invasion, these methodological approaches have been validated:

• siRNA-mediated knockdown: Transfection of cancer cell lines with validated siRNA sequences targeting TCIRG1 (as detailed in question 2.1) provides a foundation for functional studies .

• Transwell migration assays: Following TCIRG1 knockdown, transwell migration experiments have successfully demonstrated that TCIRG1 silencing inhibits the migration potential of kidney cancer cells. This approach can be adapted for studying other cancer types .

• Matrix metalloproteinase (MMP) expression analysis: Quantification of MMP-2 and MMP-9 expression following TCIRG1 knockdown can provide mechanistic insights, as these proteases are crucial for invasive capacity. Previous studies in other cancer models have shown TCIRG1 knockdown decreased MMP-2 and MMP-9 expression .

• Epithelial-mesenchymal transition (EMT) marker assessment: Analysis of EMT markers after TCIRG1 manipulation can reveal potential mechanisms, as prior research indicated TCIRG1 may promote tumor migration via EMT in hepatocellular carcinoma .

These approaches collectively provide comprehensive analysis of TCIRG1's functional role in cancer cell migration and invasion capabilities .

How can researchers investigate the relationship between TCIRG1 and genetic alterations in cancer?

To explore the relationship between TCIRG1 and genetic alterations in cancer, researchers can implement these methodological approaches:

• Mutation correlation analysis: Research has shown TCIRG1 expression correlates with specific mutation patterns in ccRCC, including fewer PBRM1 mutations and more BAP1 mutations in high TCIRG1-expressing tumors . This analytical approach can be extended to other cancer types by:

  • Dividing samples into high and low TCIRG1 expression groups

  • Comparing mutation frequencies between groups

  • Identifying significantly associated mutations

• DNA methylation analysis: TCIRG1 expression has been linked to altered DNA methylation patterns that may influence prognosis. Researchers should examine the relationship between DNA methylation and TCIRG1 expression using:

  • Correlation analysis between TCIRG1 expression and methylation levels

  • Survival analysis based on TCIRG1 DNA methylation levels

  • Integration of expression and methylation data to identify regulatory mechanisms

• Cancer stemness assessment: Utilizing RNA sequencing based on mRNA expression and DNA methylation data to determine tumor stemness and its relationship with TCIRG1 expression can reveal mechanisms by which TCIRG1 influences tumor progression and immune cell interactions .

These analytical approaches provide a comprehensive framework for exploring TCIRG1's relationship with genetic and epigenetic alterations in cancer .

What bioinformatic approaches can be used to identify and validate TCIRG1-associated gene networks?

Several validated bioinformatic approaches can be employed to identify and analyze TCIRG1-associated gene networks:

• Co-expression network construction:

  • Retrieve RNA sequencing data from relevant databases (e.g., TCGA)

  • Compute co-expressed genes using "limma" R package

  • Verify relationships using Pearson's correlation

  • Apply selection criteria: False Discovery Rate (FDR) < 0.01 and absolute Pearson's correlation > 0.4

• Functional annotation of co-expressed genes:

  • Implement "ClusterProfiler" R package for Gene Ontology (GO) analysis across:

    • Biological processes (GO_BP)

    • Cellular components (GO_CC)

    • Molecular functions (GO_MF)

  • Perform Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis

• Integration with drug sensitivity data:

  • Utilize the "pRRophetic" package to determine half-maximal inhibitory doses (IC50) of medications with varying sensitivities across high and low TCIRG1 expression groups

  • Identify drugs with differential effectiveness based on TCIRG1 expression level

These approaches provide a robust framework for understanding the broader functional networks and potential therapeutic implications associated with TCIRG1 expression .

How can researchers investigate the mechanistic link between TCIRG1 and V-ATPase activity in cancer progression?

To investigate the mechanistic relationship between TCIRG1 (also known as V-ATPase-a3) and V-ATPase activity in cancer progression:

• Lysosomal acidification assessment:

  • Utilize LysoTracker or acridine orange staining following TCIRG1 knockdown or overexpression

  • Quantify changes in intracellular pH using ratiometric pH-sensitive fluorescent probes

  • These approaches directly measure the functional impact of TCIRG1 modulation on acidification processes

• V-ATPase complex component analysis:

  • Perform co-immunoprecipitation to examine interactions between TCIRG1 and other V-ATPase subunits

  • Use blue native PAGE to analyze intact V-ATPase complex formation with and without TCIRG1

  • These methods reveal how TCIRG1 contributes to V-ATPase complex assembly and stability

• ATP hydrolysis activity measurement:

  • Implement biochemical assays to measure ATP hydrolysis rates in membrane fractions following TCIRG1 manipulation

  • This directly quantifies the enzymatic activity of the V-ATPase complex

• Pharmacologic intervention:

  • Compare effects of TCIRG1 knockdown with specific V-ATPase inhibitors (e.g., Bafilomycin A1)

  • Assess whether TCIRG1 knockdown phenotypes can be rescued by manipulating pH through alternative mechanisms

  • These approaches help distinguish TCIRG1's direct V-ATPase-related functions from potential independent roles

Understanding these mechanistic relationships provides crucial insights into how TCIRG1 promotes cancer progression through its role in cellular acidification and potential additional functions .

What criteria should be used to validate TCIRG1 antibody specificity for research applications?

Comprehensive validation of TCIRG1 antibody specificity requires multiple complementary approaches:

• Genetic knockdown/knockout controls:

  • Validate antibody specificity using siRNA-mediated knockdown (using validated sequences mentioned in section 2.1)

  • Compare staining/signal patterns between control and TCIRG1-depleted samples across applications (WB, IHC, IF)

  • Complete signal loss or significant reduction confirms specificity

• Multi-application concordance:

  • Verify consistent TCIRG1 detection across WB, IHC, and IF applications

  • Cross-validate with orthogonal detection methods (e.g., mass spectrometry)

  • Consistent protein detection across techniques provides strong evidence of specificity

• Recombinant protein competition:

  • Pre-incubate antibody with purified recombinant TCIRG1 protein

  • Specific antibodies will show reduced or eliminated signal in subsequent applications

  • This approach directly tests epitope specificity

• Published application verification:

  • Review the published applications including KD/KO (2 publications), WB (5 publications), IHC (3 publications), and IF (2 publications) that have successfully used this antibody

  • Replicate key experimental conditions from these validated protocols

These multi-layered validation approaches ensure antibody specificity before proceeding with critical research applications .

How can researchers optimize TCIRG1 antibody performance in challenging tissue samples?

For optimizing TCIRG1 antibody performance in challenging tissue samples:

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative approach: Citrate buffer pH 6.0

  • Systematic comparison of retrieval conditions (temperature, duration, buffer) may be necessary for difficult samples

• Signal amplification strategies:

  • For weak signals in IHC: Implement tyramide signal amplification (TSA) system

  • For IF applications with low signal: Consider using biotinylated secondary antibodies with streptavidin-conjugated fluorophores

  • These approaches can enhance detection sensitivity while maintaining specificity

• Fixation considerations:

  • Optimize fixation protocols as overfixation may mask TCIRG1 epitopes

  • For frozen sections, test both acetone and paraformaldehyde fixation methods

  • Different fixatives may preserve different epitopes, affecting antibody binding

• Background reduction techniques:

  • Implement dual blocking with both protein blocking solution and animal serum

  • Include additional washing steps with PBS containing 0.1-0.3% Triton X-100

  • These approaches minimize non-specific binding in challenging samples

These optimization strategies improve detection sensitivity and specificity in difficult tissue samples without compromising data integrity .